The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2016 | Trial of vadastuximab talirine combined with 7+3 induction therapy for newly diagnosed AML patients
Harry Erba
• 3 Dec 2016
Press brief by Harry Erba, MD, PhD, of The University of Alabama At Birmingham, Birmingham, AL, on a Phase 1b Study of vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed acute myeloid leukemia (AML) at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
